0001193125-24-151729.txt : 20240531 0001193125-24-151729.hdr.sgml : 20240531 20240531160556 ACCESSION NUMBER: 0001193125-24-151729 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240529 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20240531 DATE AS OF CHANGE: 20240531 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aligos Therapeutics, Inc. CENTRAL INDEX KEY: 0001799448 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39617 FILM NUMBER: 241009652 BUSINESS ADDRESS: STREET 1: ONE CORPORATE DR., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (800) 466-6059 MAIL ADDRESS: STREET 1: ONE CORPORATE DR., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 d808483d8k.htm 8-K 8-K
false 0001799448 0001799448 2024-05-29 2024-05-29

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 29, 2024

 

 

Aligos Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39617   82-4724808

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification Number)

 

One Corporate Dr., 2nd Floor

South San Francisco, CA

   94080
(Address of principal executive offices)   (Zip Code)

(800) 466-6059

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol

  

Name of each exchange
on which registered

Common Stock, $0.0001 par value per share   ALGS  

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On May 29, 2024, Aligos Therapeutics, Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC regarding its noncompliance with Nasdaq Listing Rule 5605 (“Rule 5605”), which requires, among other things, that the Audit Committee (the “Audit Committee”) of the Board of Directors of the Company (the “Board”) be comprised of a minimum of three independent directors.

As previously disclosed, Jack Nielsen resigned as a member of the Board and all committees of the Board, including the Audit Committee, effective as of May 21, 2024, resulting in the noncompliance. In accordance with Nasdaq Listing Rule 5605(c)(4), the Company was granted a cure period in order to regain compliance with Rule 5605 lasting (i) until the earlier of the Company’s next annual shareholders’ meeting or May 21, 2025; or (ii) if the next annual shareholders’ meeting is held before November 18, 2024, then no later than November 18, 2024. As the Company plans to hold its next annual shareholders’ meeting on June 27, 2024, the Company expects that the applicable end of the cure period will be November 18, 2024. The Company intends to appoint a third independent director to the Audit Committee, and thereby regain compliance with Rule 5605, prior to the end of the cure period.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ALIGOS THERAPEUTICS, INC.
Date: May 31, 2024     By:  

/s/ Lesley Ann Calhoun

      Lesley Ann Calhoun
      Executive Vice President, Chief Financial Officer
 EX-101.SCH 2 algs-20240529.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 algs-20240529_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 algs-20240529_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
May 29, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001799448
Document Type 8-K
Document Period End Date May 29, 2024
Entity Registrant Name Aligos Therapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39617
Entity Tax Identification Number 82-4724808
Entity Address, Address Line One One Corporate Dr.
Entity Address, Address Line Two 2nd Floor
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (800)
Local Phone Number 466-6059
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol ALGS
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports algs-20240529.xsd algs-20240529_lab.xml algs-20240529_pre.xml d808483d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d808483d8k.htm": { "nsprefix": "algs", "nsuri": "http://aligos.com/20240529", "dts": { "schema": { "local": [ "algs-20240529.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "algs-20240529_lab.xml" ] }, "presentationLink": { "local": [ "algs-20240529_pre.xml" ] }, "inline": { "local": [ "d808483d8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-05-29_to_2024-05-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d808483d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-05-29_to_2024-05-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d808483d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://aligos.com//20240529/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001193125-24-151729-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-151729-xbrl.zip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end XML 16 d808483d8k_htm.xml IDEA: XBRL DOCUMENT 0001799448 2024-05-29 2024-05-29 false 0001799448 8-K 2024-05-29 Aligos Therapeutics, Inc. DE 001-39617 82-4724808 One Corporate Dr. 2nd Floor South San Francisco CA 94080 (800) 466-6059 false false false false Common Stock, $0.0001 par value per share ALGS NASDAQ true false